Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ovarian Cancer: Update Bulletin [December 2015]

Product Code:
596200435
Publication Date:
December 2015
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events with the potential to shape the targeted treatment of ovarian cancer (OC). Topics covered include opinions about the potential of AstraZeneca’s PARP inhibitor, Lynparza (olaparib), to benefit patients with BRCA- wildtype OC in light of recent data. KOLs also provide related insight into how Lynparza compares with Clovis’ PARP inhibitor, rucaparib, and Merck & Co/Tesaro’s niraparib (MK-4827) in terms of its potential to treat both BRCA-mutated and BRCA-wildtype OC, and their current practice regarding testing for the BRCA mutation and use of Lynparza. In addition, KOLs give their views on the development of checkpoint inhibitors for the treatment of OC, including those which have already become established in other malignancies, such as melanoma and lung cancer, and have now reached Phase II trials for OC: Merck & Co.’s PD-1 inhibitor pembrolizumab (Keytruda) and Bristol-Myers Squibb’s PD-1 inhibitor nivolumab (Opdivo) and CTLA-4 inhibitor ipilimumab (Yervoy).

Key Questions Answered in this Update Bulletin:

  • How do KOLs view the potential of AstraZeneca’s Lynparza (olaparib), Clovis’ rucaparib and Merck & Co.’s/Tesaro’s niraparib for the treatment of BRCA-wildtype ovarian cancer (OC)?
  • What will drive the relative uptake of Lynparza, rucaparib and niraparib in the BRCA- wildtype stetting?
  • How does the current use of Lynparza for BRCA-mutated patients vary across select EU markets and the US?
  • What regulatory hurdles are delaying the uniform uptake of Lynparza across the EU and US?
  • How do KOLs view the potential of checkpoint inhibitors as a treatment approach in OC, and what safety concerns are there over the use of checkpoint inhibitors in combination?
  • Why does the clinical development of checkpoint inhibitors for OC lag behind some other malignancies, and what is the likelihood that the checkpoint inhibitors in Phase II development will reach registration?
  • Where are the potential opportunities for checkpoint inhibitors in the OC treatment paradigm, and what will be the critical strategic considerations?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved